ArticleDrug and alcohol dependence2026
Enhancing data compatibility in an evolving landscape: Medical cannabis and polysubstance use protocols in the PhenX Toolkit.
Article in Drug and alcohol dependence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mapping and measuring addiction recovery: Recommended protocols through the PHENX toolkit.Drug and alcohol dependence · 2026Review
- Refining a Novel Measure of Polysubstance Use: Applying the Cognitive Interview Method with People Who Use Drugs.Substance use & misuse · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
introductionWith increasing legalization of medical cannabis and prevalence of polysubstance use in the United States comes the need for standard psychometrically validated measures to study these substances' health effects in the population. The PhenX (consensus measures for Phenotypes and eXposures) Toolkit (www.phenxtoolkit.org) is a freely accessible catalog of recommended measurement protocols to promote data compatibility across studies, but this extensive catalog did not include measures in these important areas.
methodsIn 2024, a PhenX Working Group of experts followed a well-established consensus process to identify and recommend measurement protocols suitable for inclusion in studies on medical cannabis and polysubstance use. The broader scientific community was invited to review and provide feedback that was considered in the process of finalizing recommendations.
resultsIn 2025, the PhenX Toolkit released 15 new medical cannabis and polysubstance use protocols, which assess medical and other cannabis use-including consumption levels, product types, sources, motives, expectancies, medical card status, provider-patient communication, and biochemical validation-as well as polysubstance use patterns and related overdose risk. These protocols complement existing substance-related content in PhenX Toolkit and facilitate future development of knowledge on health effects of cannabis and polysubstance use and clinical guidance on safety or dosing for medical cannabis.
conclusionResearchers are encouraged to adopt these measurement protocols, so results across studies can be better compared and combined to efficiently and reliably evaluate the health effects of medical cannabis and polysubstance use. Measures in these domains will continue to be updated as new knowledge is gained.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.